2. Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol. 2004;15:541-548.
3. D’Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981;99:257-261.
4. Flach AJ, Dolan BJ, Sudduth B, Weddell J. Amiodarone-induced lens opacities. Arch Ophthalmol. 1983;101:1554-1556.
5. Uçakhan OO, Kanpolat A, Ylmaz N, Ozkan M. Amiodarone keratopathy: an in vivo confocal microscopy study. Eye Contact Lens. 2005;31:148-157.
- Abstract viewed - 147 times
- 553 PDF downloaded - 75 times
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
© Deepti Mahajan, 2020
Affiliations
Deepti Mahajan
Senior resident ophthalmology
Anil Verma
Affiliation not stated
Rajesh Sharma
Affiliation not stated
How to Cite
Amiodarone-induced vortex keratopathy at a low maintenance dose
Vol 17 No 2 (2020): Asian Journal of Ophthalmology
Submitted: May 23, 2018
Published: Apr 30, 2020
Abstract
Vortex keratopathy is a common side effect of amiodarone, which is a class III antiarrhythmic agent. We describe a 50-year-old man who developed vortex keratopahy with amiodarone 200 mg BD for atrial fibrillation since two years. The daily (400 mg/day) and cumulative dose (100 g) combined with the length of therapy is associated with the toxicity. Toxic effects may also be observed at lower maintenance doses, as observed in this patient. This case indicates that multi-organ toxicity due to amiodarone may develop even with short-term use and a low maintenance dose. Having been off the medication for two months, it is expected that the deposition pattern will diminish, as is the case for the vast majority of patients.